

*To the Copenhagen Stock Exchange
and the Press*

Release no. 17/2002

Pharmexa – Change of Financial Calendar 2002

The release of the interim financial report, H1 2002 scheduled for August 22, 2002 has been moved to August 21, 2002. Furthermore, Pharmexa is planning an Extraordinary General Meeting on August 21, 2002 to elect Claus Bræstrup new member of the Board of Directors. Pharmexa's Financial Calendar for the remainder of 2002 is as follows:

| | |
|-------------------|---|
| August 21, 2002 | Release of interim financial report, H1 2002 |
| August 21, 2002 | Extraordinary General Meeting |
| November 21, 2002 | Release of interim financial report, 3rd quarter 2002 |

Hørsholm, July 30, 2002

Jakob Schmidt
Chief Financial Officer

Additional information:

Søren Mouritsen, chief executive officer, telephone +45 4516 2525
Jakob Schmidt, chief financial officer, telephone +45 4516 2525

Note to editors:

Pharmexa A/S (CSE: PHARMX) is a leading company in the field of therapeutic vaccines for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac™ pharmaccine technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases. Pharmexa's research and development programs are targeted towards breast cancer, asthma, bone degeneration, allergy and neurodegenerative diseases. The Pharmexa Group has entered into collaborative agreements with Lexigen/Merck KGaA, Ferring, Schering-Plough, H. Lundbeck, NeuroSearch, GlaxoSmithKline, Zycos, Epimmune and AstraZeneca. The Group has 153 employees. More information on Pharmexa can be found on www.pharmexa.com.